Gaspar Aspas Requena

Optical Genome Mapping in Routine Cytogenetic Diagnosis of Acute Leukemia

Gwendoline Soler, Zangbéwendé Guy Ouedraogo, Carole Goumy et al. · Cancers · 2023 · 19 citations · Full text

Life Sciences, Genetics, Hematology +17

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

Sylvain Garciaz, Pierre‐Yves Dumas, Sarah Bertoli et al. · American Journal of Hematology · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Curtis A. Lachowiez, Maël Heiblig, Gaspar Aspas Requena et al. · Blood Cancer Discovery · 2025 · 13 citations · Full text

Life Sciences, Genetics, Hematology +15

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A. Sallman et al. · Blood · 2023 · 12 citations

Medicine, Hematology, Pharmacology +17

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena et al. · Blood · 2023 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +17